HALIFAX, NOVA SCOTIA--(Marketwired - May 21, 2015) - Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at two upcoming U.S. investor-focused conferences, the 2015 Marcum MicroCap Conference, held May 27-28, 2015 in New York, NY and the LD Micro Invitational 2015, held June 1-3, 2015 in Los Angeles, CA.

Details of Immunovaccine's presentations are as follows:

Event: 2015 Marcum MicroCap Conference
Thursday, May 28, 2015
Time: 4:00 - 5:00 EDT
Location: Uris Room, Grand Hyatt New York

The annual Marcum MicroCap Conference is a showcase for public companies with less than $500 million in market capitalization. For more information please visit the conference website at http://www.marcumllp.com/microcap.

Event: LD Micro Invitational 2015
Monday, June 1, 2015
Time: 1:30 - 2:00 pm PDT
Location: Track Room 4, Luxe Sunset Bel Air Hotel

This 5th annual conference will feature 185 companies in the small/micro-cap space. For more information, please visit the conference website at http://www.ldmicro.com/.

Marc Mansour, Ph.D., Chief Executive Officer of Immunovaccine, will present a corporate update including the latest developments for the Company's lead clinical-stage cancer immunotherapy DPX-Survivac.

About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. Survivin has been recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in solid tumors and blood cancers including ovarian, breast, colon and lung cancers, among others. Survivin plays an essential role in antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to various anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in high percentage of cancer patients.

The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to actively search for tumor cells expressing survivin and destroy them.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.

Connect at www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Contact Information:

Immunovaccine Inc.
Marc Mansour
Chief Executive Officer
(902) 492-1819

Immunovaccine Inc.
Investor Relations
(902) 492-1819